Pre-surgical sunitinib treatment enabling nephron-sparing surgery in a patient with renal cell carcinoma in a solitary kidney.
Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Published Article
Nagoya journal of medical science
- Publication Date
May 01, 2019
A 55-year-old man with a solitary kidney was diagnosed with an 8.5 cm renal cell carcinoma in the right kidney without metastasis. Twenty five months of sunitinib treatment reduced the tumor from 8.5 to 5.5 cm and enabled nephron-sparing surgery. He has no evidence of recurrence 58 months after the surgery.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 12/31/2019 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/31239602